Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD2 | Q9Y5L3 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520518 | 1.00 | ENTPD2 (0.34) | ENTPD2TDP1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12212785 | 0.91 | TDP1 (0.36) | ENTPD2TDP1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2519740 | 0.91 | TDP1 (0.36) | ENTPD2TDP1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29707946 | 0.87 | TDP1 (0.35) | ENTPD2TDP1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25608882 | 0.87 | TDP1 (0.35) | ENTPD2TDP1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16243030 | 0.87 | SLC28A1 (0.33) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1317537 | 0.85 | TDP1 (0.36) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1318516 | 0.85 | TDP1 (0.41) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL16243336 | 0.85 | TDP1 (0.33) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18034250 | 0.85 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039611-B2 | 2′-hydroxyl group-modified ribonucleoside derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | RNASEH1, RNASEL, NSUN2 | ENTPD2 877/4885TDP1 439/4885SLC28A1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.